JNJ
嬌生 JOHNSON & JOHNSON
+1.48 (+0.55%)268.76USD1.9M成交股數648B市值31.2本益比(近四季)6.6股價營收比+6.6%營收年增(近四季)2026-10-13下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 10 · 67.8M · 5 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 70.2M |
| 近 180 天 淨額 | −70.2M |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-02 | 09-04 | Schmid Timothy | EVP, WW Chair, MedTech | S 公開市場賣出 | 11.1K | 274.74 | 3.0M | 25.4K | SEC |
| 2026-09-02 | 09-04 | Schmid Timothy | EVP, WW Chair, MedTech | M 選擇權執行 | 11.1K | 131.94 | 1.5M | 36.5K | SEC |
| 2026-09-02 | 09-04 | Schmid Timothy | EVP, WW Chair, MedTech | M 選擇權執行 | 22.5K | 151.41 | 3.4M | 48.0K | SEC |
| 2026-09-02 | 09-04 | Schmid Timothy | EVP, WW Chair, MedTech | S 公開市場賣出 | 22.5K | 274.74 | 6.2M | 25.4K | SEC |
| 2026-08-17 | 08-18 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M 選擇權執行 | 15.0K | 115.67 | 1.7M | 209K | SEC |
| 2026-08-17 | 08-18 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | S 公開市場賣出 | 15.0K | 263.36 | 4.0M | 194K | SEC |
| 2026-08-13 | 08-14 | Duato Joaquin | CEO and Chairman of the Board | S 公開市場賣出 | 21.0K | 262.00 | 5.5M | 378K | SEC |
| 2026-08-13 | 08-14 | Duato Joaquin | CEO and Chairman of the Board | S 公開市場賣出 | 102K | 261.00 | 26.7M | 276K | SEC |
| 2026-08-13 | 08-14 | Duato Joaquin | CEO and Chairman of the Board | M 選擇權執行 | 123K | 115.67 | 14.3M | 399K | SEC |
| 2026-08-06 | 08-07 | Forminard Elizabeth | EVP, Chief Legal Officer | M 選擇權執行 | 9.3K | 131.94 | 1.2M | 32.9K | SEC |
| 2026-08-06 | 08-07 | Forminard Elizabeth | EVP, Chief Legal Officer | S 公開市場賣出 | 9.3K | 257.76 | 2.4M | 23.6K | SEC |
| 2026-08-06 | 08-07 | Forminard Elizabeth | EVP, Chief Legal Officer | S 公開市場賣出 | 6.6K | 255.93 | 1.7M | 17.0K | SEC |
| 2026-08-05 | 08-07 | Duato Joaquin | CEO and Chairman of the Board | S 公開市場賣出 | 42.0K | 258.06 | 10.8M | 282K | SEC |
| 2026-08-05 | 08-07 | Duato Joaquin | CEO and Chairman of the Board | S 公開市場賣出 | 6.5K | 258.74 | 1.7M | 276K | SEC |
| 2026-07-20 | 07-21 | Broadhurst Vanessa | EVP, Global Corp Affairs | S 公開市場賣出 | 23.1K | 251.27 | 5.8M | 23.0K | SEC |
| 2026-07-20 | 07-21 | Broadhurst Vanessa | EVP, Global Corp Affairs | M 選擇權執行 | 11.9K | 131.94 | 1.6M | 46.1K | SEC |
| 2026-07-20 | 07-21 | Broadhurst Vanessa | EVP, Global Corp Affairs | M 選擇權執行 | 11.1K | 129.51 | 1.4M | 34.1K | SEC |
| 2026-06-11 | 06-12 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M 選擇權執行 | 10.0K | 115.67 | 1.2M | 124K | SEC |
| 2026-06-11 | 06-12 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | S 公開市場賣出 | 10.0K | 241.15 | 2.4M | 114K | SEC |
| 2026-05-01 | 05-04 | REED JOHN C | EVP, Innovative Medicine, R&D | F 繳稅扣股 | 11.0K | 229.85 | 2.5M | 24.9K | SEC |
| 2026-05-01 | 05-04 | REED JOHN C | EVP, Innovative Medicine, R&D | M 選擇權執行 | 25.3K | – | – | 35.9K | SEC |
| 2026-02-27 | 03-03 | Decker Robert J | VP Corporate Controller | M 選擇權執行 | 4.1K | 115.67 | 471K | 27.8K | SEC |
| 2026-02-27 | 03-03 | Decker Robert J | VP Corporate Controller | S 公開市場賣出 | 4.1K | 247.87 | 1.0M | 23.7K | SEC |
| 2026-02-20 | 02-23 | Schmid Timothy | EVP, WW Chair, MedTech | S 公開市場賣出 | 1.3K | 245.66 | 325K | 25.4K | SEC |
| 2026-02-18 | 02-18 | Schmid Timothy | EVP, WW Chair, MedTech | S 公開市場賣出 | 9.0K | 244.53 | 2.2M | 26.8K | SEC |
| 2026-02-18 | 02-18 | Schmid Timothy | EVP, WW Chair, MedTech | S 公開市場賣出 | 13.6K | 244.20 | 3.3M | 26.8K | SEC |
| 2026-02-18 | 02-18 | Schmid Timothy | EVP, WW Chair, MedTech | M 選擇權執行 | 13.6K | 115.67 | 1.6M | 40.4K | SEC |
| 2026-02-18 | 02-18 | Schmid Timothy | EVP, WW Chair, MedTech | M 選擇權執行 | 9.0K | 129.51 | 1.2M | 35.8K | SEC |
| 2026-02-17 | 02-18 | Wolk Joseph J | Exec VP, CFO | M 選擇權執行 | 33.4K | 131.94 | 4.4M | 72.3K | SEC |
| 2026-02-17 | 02-18 | Wolk Joseph J | Exec VP, CFO | S 公開市場賣出 | 33.4K | 242.75 | 8.1M | 39.0K | SEC |
| 2026-02-17 | 02-18 | Wolk Joseph J | Exec VP, CFO | S 公開市場賣出 | 25.0K | 242.68 | 6.1M | 14.0K | SEC |
| 2026-02-17 | 02-18 | Wolk Joseph J | Exec VP, CFO | S 公開市場賣出 | 19.2K | 242.99 | 4.7M | 39.0K | SEC |
| 2026-02-17 | 02-18 | Wolk Joseph J | Exec VP, CFO | M 選擇權執行 | 19.2K | 115.67 | 2.2M | 58.2K | SEC |
| 2026-02-17 | 02-18 | Wolk Joseph J | Exec VP, CFO | M 選擇權執行 | 12.1K | 129.51 | 1.6M | 51.0K | SEC |
| 2026-02-17 | 02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | M 選擇權執行 | 29.9K | 156.15 | 4.7M | 42.9K | SEC |
| 2026-02-17 | 02-18 | Broadhurst Vanessa | EVP, Global Corp Affairs | S 公開市場賣出 | 6.2K | 243.39 | 1.5M | 23.0K | SEC |
| 2026-02-17 | 02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | M 選擇權執行 | 21.7K | 157.92 | 3.4M | 34.7K | SEC |
| 2026-02-17 | 02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | S 公開市場賣出 | 29.9K | 243.00 | 7.3M | 12.9K | SEC |
| 2026-02-17 | 02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | S 公開市場賣出 | 2.3K | 243.00 | 555K | 10.7K | SEC |
| 2026-02-17 | 02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | S 公開市場賣出 | 21.7K | 243.00 | 5.3M | 12.9K | SEC |
| 2026-02-17 | 02-18 | Swanson James D. | EVP, CIO | M 選擇權執行 | 20.5K | 164.62 | 3.4M | 46.2K | SEC |
| 2026-02-17 | 02-18 | Swanson James D. | EVP, CIO | S 公開市場賣出 | 20.5K | 242.70 | 5.0M | 25.7K | SEC |
| 2026-02-17 | 02-18 | Wolk Joseph J | Exec VP, CFO | S 公開市場賣出 | 12.1K | 242.87 | 2.9M | 39.0K | SEC |
| 2026-02-15 | 02-18 | Mulholland Kristen | EVP, Chief HR Officer | M 選擇權執行 | 575 | – | – | 20.1K | SEC |
| 2026-02-15 | 02-18 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M 選擇權執行 | 1.8K | – | – | 195K | SEC |
| 2026-02-15 | 02-18 | Mulholland Kristen | EVP, Chief HR Officer | F 繳稅扣股 | 251 | 243.45 | 61K | 19.8K | SEC |
| 2026-02-15 | 02-18 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M 選擇權執行 | 1.6K | – | – | 194K | SEC |
| 2026-02-15 | 02-18 | Mulholland Kristen | EVP, Chief HR Officer | M 選擇權執行 | 419 | – | – | 19.7K | SEC |
| 2026-02-15 | 02-18 | Mulholland Kristen | EVP, Chief HR Officer | F 繳稅扣股 | 172 | 243.45 | 42K | 19.5K | SEC |
| 2026-02-15 | 02-18 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M 選擇權執行 | 606 | – | – | 114K | SEC |
| 2026-02-15 | 02-18 | Schmid Timothy | EVP, WW Chair, MedTech | F 繳稅扣股 | 448 | 243.45 | 109K | 26.8K | SEC |
| 2026-02-15 | 02-18 | Schmid Timothy | EVP, WW Chair, MedTech | M 選擇權執行 | 1.0K | – | – | 27.2K | SEC |
| 2026-02-15 | 02-18 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F 繳稅扣股 | 310 | 243.45 | 75K | 114K | SEC |
| 2026-02-15 | 02-18 | Schmid Timothy | EVP, WW Chair, MedTech | F 繳稅扣股 | 15 | 243.45 | 4K | 26.2K | SEC |
| 2026-02-15 | 02-18 | Schmid Timothy | EVP, WW Chair, MedTech | M 選擇權執行 | 1.0K | – | – | 26.2K | SEC |
| 2026-02-15 | 02-18 | Broadhurst Vanessa | EVP, Global Corp Affairs | M 選擇權執行 | 492 | – | – | 29.2K | SEC |
| 2026-02-15 | 02-18 | Duato Joaquin | CEO and Chairman of the Board | F 繳稅扣股 | 2.0K | 243.45 | 477K | 324K | SEC |
| 2026-02-15 | 02-18 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F 繳稅扣股 | 816 | 243.45 | 199K | 194K | SEC |
| 2026-02-15 | 02-18 | Duato Joaquin | CEO and Chairman of the Board | M 選擇權執行 | 4.5K | – | – | 326K | SEC |
| 2026-02-15 | 02-18 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F 繳稅扣股 | 945 | 243.45 | 230K | 194K | SEC |
| 2026-02-15 | 02-18 | Broadhurst Vanessa | EVP, Global Corp Affairs | M 選擇權執行 | 526 | – | – | 29.5K | SEC |
| 2026-02-15 | 02-18 | Broadhurst Vanessa | EVP, Global Corp Affairs | F 繳稅扣股 | 252 | 243.45 | 61K | 28.9K | SEC |
| 2026-02-15 | 02-18 | Wolk Joseph J | Exec VP, CFO | M 選擇權執行 | 1.9K | – | – | 39.8K | SEC |
| 2026-02-15 | 02-18 | Wolk Joseph J | Exec VP, CFO | F 繳稅扣股 | 817 | 243.45 | 199K | 39.0K | SEC |
| 2026-02-15 | 02-18 | Duato Joaquin | CEO and Chairman of the Board | M 選擇權執行 | 3.7K | – | – | 324K | SEC |
| 2026-02-15 | 02-18 | Decker Robert J | VP Corporate Controller | F 繳稅扣股 | 95 | 243.45 | 23K | 23.7K | SEC |
| 2026-02-15 | 02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | M 選擇權執行 | 1.8K | – | – | 13.5K | SEC |
| 2026-02-15 | 02-18 | Decker Robert J | VP Corporate Controller | M 選擇權執行 | 344 | – | – | 23.8K | SEC |
| 2026-02-15 | 02-18 | Wolk Joseph J | Exec VP, CFO | M 選擇權執行 | 2.0K | – | – | 38.8K | SEC |
| 2026-02-15 | 02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | F 繳稅扣股 | 385 | 243.45 | 94K | 11.6K | SEC |
| 2026-02-15 | 02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | M 選擇權執行 | 1.3K | – | – | 12.0K | SEC |
| 2026-02-15 | 02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | F 繳稅扣股 | 528 | 243.45 | 129K | 12.9K | SEC |
| 2026-02-15 | 02-18 | Forminard Elizabeth | EVP, Chief Legal Officer | F 繳稅扣股 | 544 | 243.45 | 132K | 23.6K | SEC |
| 2026-02-15 | 02-18 | Forminard Elizabeth | EVP, Chief Legal Officer | M 選擇權執行 | 1.1K | – | – | 24.1K | SEC |
| 2026-02-15 | 02-18 | Forminard Elizabeth | EVP, Chief Legal Officer | F 繳稅扣股 | 492 | 243.45 | 120K | 23.0K | SEC |
| 2026-02-15 | 02-18 | Forminard Elizabeth | EVP, Chief Legal Officer | M 選擇權執行 | 961 | – | – | 23.5K | SEC |
| 2026-02-15 | 02-18 | Broadhurst Vanessa | EVP, Global Corp Affairs | F 繳稅扣股 | 270 | 243.45 | 66K | 29.2K | SEC |
| 2026-02-15 | 02-18 | Duato Joaquin | CEO and Chairman of the Board | F 繳稅扣股 | 1.6K | 243.45 | 390K | 322K | SEC |
| 2026-02-15 | 02-18 | Decker Robert J | VP Corporate Controller | M 選擇權執行 | 339 | – | – | 23.5K | SEC |
| 2026-02-15 | 02-18 | Decker Robert J | VP Corporate Controller | F 繳稅扣股 | 94 | 243.45 | 23K | 23.4K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| BlackRock, Inc. | 212M | 53.9B | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 157M | 39.9B | 新進 | 新進 |
| STATE STREET CORP | 134M | 34.0B | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 64.4M | 16.3B | 新進 | 新進 |
| JPMORGAN CHASE & CO | 58.3M | 15.1B | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 59.1M | 15.0B | 新進 | 新進 |
| MORGAN STANLEY | 44.8M | 11.4B | 新進 | 新進 |
| 挪威主權基金 NORGES BANK | 31.8M | 8.1B | 新進 | 新進 |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 31.6M | 8.0B | 新進 | 新進 |
| NORTHERN TRUST CORP | 28.8M | 7.3B | 新進 | 新進 |
| BANK OF AMERICA CORP /DE/ | 23.4M | 6.0B | 新進 | 新進 |
| FMR LLC | 22.6M | 5.7B | 新進 | 新進 |
| WELLINGTON MANAGEMENT GROUP LLP | 22.6M | 5.7B | 新進 | 新進 |
| Bank of New York Mellon Corp | 21.7M | 5.5B | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 19.7M | 5.0B | 新進 | 新進 |
| Legal & General Group Plc | 19.3M | 4.9B | 新進 | 新進 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 19.1M | 4.9B | 新進 | 新進 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 18.4M | 4.7B | 新進 | 新進 |
| WELLS FARGO & COMPANY/MN | 17.4M | 4.4B | 新進 | 新進 |
| Invesco Ltd. | 15.7M | 4.0B | 新進 | 新進 |
| DEUTSCHE BANK AG\ | 15.7M | 4.0B | 新進 | 新進 |
| DIMENSIONAL FUND ADVISORS LP | 15.4M | 3.9B | 新進 | 新進 |
| Capital World Investors | 15.2M | 3.9B | 新進 | 新進 |
| VANGUARD FIDUCIARY TRUST CO | 13.5M | 3.4B | 新進 | 新進 |
| AMERIPRISE FINANCIAL INC | 13.4M | 3.4B | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 4,677 +24 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 4677 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 1.80B · 74.7% |
| 合計季末市值 | 443B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 21.7M |
|---|---|
| 與上期比 | +0.4% |
| 佔流通股數 | 0.90% |
| 日均成交量 | 6.6M |
| 回補天數 | 3.3 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 21.7M | +0.4% | 0.90% | 6.6M | 3.3 |
| 2026-08-14 | 21.6M | -15.0% | 0.90% | 6.5M | 3.3 |
| 2026-07-31 | 25.4M | -7.4% | 1.05% | 8.5M | 3.0 |
| 2026-07-15 | 27.4M | +3.2% | 1.14% | 7.5M | 3.7 |
| 2026-06-30 | 26.6M | -0.4% | 1.10% | 10.7M | 2.5 |
| 2026-06-15 | 26.7M | +14.0% | 1.11% | 7.4M | 3.6 |
| 2026-05-29 | 23.4M | +1.6% | 0.97% | 7.9M | 3.0 |
| 2026-05-15 | 23.0M | +3.1% | 0.96% | 7.5M | 3.1 |
| 2026-04-30 | 22.3M | +13.6% | 0.93% | 8.1M | 2.7 |
| 2026-04-15 | 19.7M | -11.7% | 0.82% | 7.1M | 2.8 |
| 2026-03-31 | 22.3M | -4.5% | 0.92% | 8.1M | 2.8 |
| 2026-03-13 | 23.3M | -7.0% | 0.97% | 7.4M | 3.2 |
| 2026-02-27 | 25.1M | +20.8% | 1.04% | 10.0M | 2.5 |
| 2026-02-13 | 20.8M | +6.2% | 0.86% | 9.1M | 2.3 |
| 2026-01-30 | 19.6M | -8.3% | 0.81% | 10.4M | 1.9 |
| 2026-01-15 | 21.3M | +4.4% | 0.88% | 8.8M | 2.4 |
| 2025-12-31 | 20.4M | -14.8% | 0.85% | 7.5M | 2.7 |
| 2025-12-15 | 24.0M | +0.3% | 0.99% | 8.5M | 2.8 |
| 2025-11-28 | 23.9M | +18.8% | 0.99% | 11.3M | 2.1 |
| 2025-11-14 | 20.1M | +3.0% | 0.83% | 7.3M | 2.8 |
| 2025-10-31 | 19.5M | -5.3% | 0.81% | 8.1M | 2.4 |
| 2025-10-15 | 20.6M | +13.5% | 0.86% | 8.9M | 2.3 |
| 2025-09-30 | 18.2M | -17.6% | 0.75% | 9.8M | 1.9 |
| 2025-09-15 | 22.1M | +17.1% | 0.92% | 7.3M | 3.0 |
| 2025-08-29 | 18.8M | +1.7% | 0.78% | 8.1M | 2.3 |
| 2025-08-15 | 18.5M | +8.0% | 0.77% | 8.6M | 2.2 |